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PURPOSE. Amblyopia is a common developmental visual impairment characterized by a
substantial difference in acuity between the two eyes. Current monocular treatments, which
promote use of the affected eye by occluding or blurring the fellow eye, improve acuity, but
are hindered by poor compliance. Recently developed binocular treatments can produce
rapid gains in visual function, thought to be as a result of reduced interocular suppression. We
set out to develop an effective home-based binocular treatment system for amblyopia that
would engage high levels of compliance but that would also allow us to assess the role of
suppression in children’s response to binocular treatment.
METHODS. Balanced binocular viewing therapy (BBV) involves daily viewing of dichoptic movies
(with ‘‘visibility’’ matched across the two eyes) and gameplay (to monitor compliance and
suppression). Twenty-two children (3–11 years) with anisometropic (n ¼ 7; group 1) and
strabismic or combined mechanism amblyopia (group 2; n ¼ 6 and 9, respectively) completed
the study. Groups 1 and 2 were treated for a maximum of 8 or 24 weeks, respectively.
RESULTS. The treatment elicited high levels of compliance (on average, 89.4% 6 24.2% of daily
dose in 68.23% 6 12.2% of days on treatment) and led to a mean improvement in acuity of
0.27 logMAR (SD 0.22) for the amblyopic eye. Importantly, acuity gains were not correlated
with a reduction in suppression.
CONCLUSIONS. BBV is a binocular treatment for amblyopia that can be self-administered at home
(with remote monitoring), producing rapid and substantial benefits that cannot be solely
mediated by a reduction in interocular suppression.
Keywords: amblyopia, binocular vision, stereoacuity, visual development
Amblyopia is a developmental disorder of vision with aprevalence of 2% to 5%,1 defined as a monocular (rarely
binocular) reduction of the best-corrected visual acuity
(henceforth, acuity) in an otherwise healthy eye. Amblyopia
is caused by a prolonged period of abnormal retinal stimulation
(mainly) due to strabismus (ocular misalignment), anisometro-
pia (refractive imbalance), or both (combined) and leads to
functional deficits, including reduced contrast sensitivity,2 poor
spatial localization,3 poor stereovision,4 and foveal crowding.5
Typically, amblyopia is treated only if the interocular acuity
difference between the amblyopic eye (AE) and the fellow eye
(FE) is at least 0.2 logMAR.6 Current treatment commences
with 12 to 24 weeks of wearing prescribed optical correction,
which improves AE acuity to normal levels in 27% to 32% of
cases.7,8 Otherwise, treatment to promote the use of the AE is
administered, which consists of patching the FE (2–12 h/d)9 or
blurring the FE with atropine eye drops10 for up to 24
months.11,12 Such occlusion therapies improve acuity in
approximately 70% of patients by 0.2 logMAR or more.9
However, their impact on binocular vision is less certain13
and amblyopia recurs within a year in approximately 25% of
patients younger than 8 years.14,15 Moreover, compliance is
poor: on average, only 44% of the prescribed daily dose is
received in 58% of days ascribed for treatment.16
Central to current treatment is the idea of a critical period
for visual development. In humans, acuity and contrast
sensitivity are adversely affected by periods of monocular
deprivation before the age of 10 years, even though adult-like
performance is reached at 6 years.17 However, the notion that
amblyopia is not treatable outside of this period has been
challenged by studies finding that adults forced to use their AE
show substantial improvements in contrast sensitivity,18 crowd-
ed acuity,19 and stereopsis.20
Interocular suppression (henceforth, suppression) is widely
considered to be central to the mechanisms underlying
amblyopia, although functional definitions vary. When mea-
sured with a dichoptic motion-coherence task,21 suppression
has been quantified as the contrast offset between the eyes at
which binocular integration fails.22,23 Others have measured
suppression as the ‘‘effective contrast ratio’’ necessary to
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perform a dichoptic phase-alignment task.24 Recently, some of
us have developed a test measuring the contrast mixture of
dichoptically presented letter-pairs that leads observers to
switch from using one eye to the other.25 In terms of
physiological mechanism, animal models have shown that
prolonged monocular deprivation leads to weakened excitato-
ry drive from the deprived eye and hence imbalanced
activation of binocular cortical neurons.26–29 The resulting
suppression is thought to be the result of an active inhibitory
cortical mechanism.30
Stronger suppression is associated with more severe
amblyopia23,31 and has traditionally been viewed as an adaptive
mechanism (to avoid double-vision).32 In contrast, it has been
proposed that suppression has a causative role in amblyopia,
making it a candidate target for therapy.31 Notably, Hess and
colleagues have developed ‘‘antisuppression’’ therapy, which
uses games (with elements split across the eyes to promote
binocularity) as a mean of treating amblyopia in adults33–35 and
children.36–38 After 2 to 6 weeks of treatment, visual acuity
improves by an average of approximately 0.15 logMAR and
stereopsis was measurable in approximately 45% of partici-
pants (for the first time in approximately two-thirds of them).
However, a randomized controlled trial of an alternative
binocular therapy (iBIT) reports only modest success with
children (mean acuity gain: 0.08 logMAR).39 Modern ‘‘percep-
tual learning’’ treatments have also yielded positive results in
adults and older children via monocular training (using the AE)
on psychophysical tasks18,40 or video-game play,41,42 as have
hybrid approaches that interleave a monocular task with
dichoptic video-game play.43 For a review on monocular and
binocular behavioral training methodologies, see Reference 44.
Although the changes in acuity and binocularity elicited by
such therapies are widely cited as examples of cortical
plasticity41,45 effected through a change in suppression,31 in
reality the mechanism(s) remains poorly understood. Here, we
describe a new variant of binocular therapy: balanced
binocular viewing treatment (BBV), which uses dichoptic
movies that are matched in visibility across the eyes. Our
procedure is designed to be both an effective home-based
treatment (engaging a high level of compliance) and a platform
for exploring how binocular therapies work.
METHODS
Participants
Twenty-four children (14 female) aged 3.5 to 11.3 years (mean
age: 6.6 6 2.9 years), with anisometropic (group 1), strabismic,
or combined mechanism amblyopia (both in group 2), were
recruited from the Richard Desmond Children’s Eye Centre at
Moorfields Eye Hospital, London. The treatment was allowed for
a maximum of 8 weeks (group 1; pilot study, see Discussion) or
24 weeks (group 2). Our research followed the tenets of the
Declaration of Helsinki and we obtained informed consent from
caregivers and assent from children before enrollment. Our
recruitment procedure and treatment regimen were approved
by the local NHS Research Ethics Committee.
Children were included if their amblyopia (defined as an
interocular acuity difference of 0.2 logMAR or greater and FE
acuity equal or better than 0.2 logMAR) persisted after a
minimum of 16 weeks of optical treatment, and if acuity in the
AE was unchanged on two consecutive visits, 8 weeks apart.
Exclusion criteria included prior amblyopia treatment other
than optical correction, presence of paralytic or restrictive
squint, other preexisting visual deficit (e.g., cataract) or
significant neurological or behavioral problems. Amblyopia
was defined as anisometropic if there was a difference of at
least 1 diopter (D) in spherical equivalent or 1.5 D in
astigmatism between the two eyes. Combined mechanism
amblyopia was also associated with heterotropia: either 10 D
(microstrabismus) or with a larger angle of deviation. Children
were classified as strabismic amblyopes if a manifest inter-
ocular misalignment greater than 10 D was present (conver-
gent or divergent), but no anisometropia. Participants’ details
are summarized in Table 1.
All children received optical treatment before participating
in our study. The mean period of optical treatment was 28 6
12 weeks: 30 6 16 weeks in children with anisometropia, 25
6 9 weeks in those with strabismus, and 29 6 12 weeks in
those with combined mechanism amblyopia.
Equipment
Our treatment uses a computer system capable of presenting
three-dimensional (3D) movies, which is installed in the child’s
home (Fig. 1A). The monitor operates at 1920 3 1080-pixel
resolution at 120 Hz (60 Hz per eye). Movies were presented
using software written in MATLAB (MathWorks, Ltd., Cam-
bridge, MA, USA) and Psychtoolbox (http://www.
psychtoolbox.org, in the public domain).46 Shutter glasses
(nVidia Corp., Santa Clara, CA, USA) were used to indepen-
dently control the image presented to the two eyes. These
were mounted in a customized children’s ski mask to ensure
comfort, while maintaining a snug fit over spectacle correc-
tion. The monitor was linearized in software based on a series
of luminance measurements (made by placing a Minolta LS110
photometer [Konica Minolta, Tokyo, Japan] behind a single
lens of a pair of goggles) to achieve a midgray of 45 cd/m2 to
each eye. Children were provided with a keypad to make
responses to the suppression task, and were encouraged to use
the 95-cm-long cable to ensure they maintained viewing
distance at approximately 1 m.
Treatment Regimen
Treatment consisted of 1 hour per day spent viewing movies
(selected by children/carers) while wearing the goggles.
Movies were presented dichoptically and the horizontal offset
between the two eyes was continuously modulated to generate
a percept of gradually changing depth. A zero-disparity
textured background was presented to both eyes to encourage
stable vergence. The child’s view of the movie (Fig. 1B, inset)
was ‘‘balanced’’ by blurring the image presented to the FE, so
that the child’s monocular acuity was matched across eyes. To
determine the level of blur required, we ran two tasks. Task 1
(Fig. 2A) quantified AE acuity as the scaling required to support
identification of the orientation of a crowded Visual-Acuity-Man
(‘‘VacMan’’).47 Targets were presented monocularly at 75%
contrast with four flanking ‘‘ghosts’’ (spaced at twice the target
width). They were masked with a 25% contrast phase–
scrambled version of the stimulus that was visible across both
eyes (to provide a vergence lock). Stimuli were scaled using an
adaptive staircase (QUEST).48 Over 45 trials, this converged on
the scaling that produced 83% correct identification. Task 2
(Fig. 2B) presented similar VacMan stimuli to the FE (scaled
with the AE threshold from task 1) and then used QUEST to
determine the level of isotropic Gaussian blur that elicited 83%
VacMan identification. This level of blur was applied to the
image presented to the FE during movie presentation, ensuring
that the images presented to the two eyes were equally visible.
During treatment, the movie was interrupted every minute
by an interactive game used to measure suppression (Fig. 2C).
Two dichoptically presented ‘‘ghosts’’ flanked a central
VacMan, either above/below or left/right. We told children
‘‘VacMan wants to eat the whitest ghost; which ghost looks the
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whitest?’’ They responded (up/down/left/right) using a key-
pad. Each ghost was composed of one dark and one light
component, presented dichoptically to each eye. The lumi-
nance of the components was set using an interocular contrast
ratio (R; 0–100%), which determines the relative strength of FE
and AE stimulation as 0%¼FE fully suppressed, 50%¼balanced
vision and 100% ¼ AE fully suppressed. For a background
luminance of Lback (here, 45 cd/m
2) with a maximum
increment/decrement of Lrange (here, 45 cd/m
2), we made
stimuli with the following algorithm:
1. Randomly select if ghosts fall above/below or left/right
(Fig. 2C) of VacMan.
2. Randomly assign the light/dark FE/AE polarity ghost to
one side of VacMan, with the opposite polarity on the
other side; for example, Fig. 2C shows a dark/light FE/AE
TABLE 1. Baseline Details of Participants (n ¼ 24)
Values corresponding to the AE are italicized. Bold indicates ‘‘severe’’ cases (i.e., acuity in the AE >0.6 logMAR; n¼ 16). Only participant 8 had
mild amblyopia, the remaining had moderate amblyopia (0.3acuity in the AE0.6 logMAR; n¼ 7). Participants 7 and 21 did not attend their clinic
appointments, hence their data are incomplete and have not been analyzed. aniso, anisometropic; astigm., astigmatism; comb., combined
mechanism; CS, convergent strabismus; DS, diopter sphere; ET, esotropia; hyperm, hypermetropia; LE, left eye; m/f, male/female; mod, moderate;
RE, right eye; sev, severe; strab., strabismic.
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ghost on the left and a light/dark FE/AE ghost on the
right of VacMan.
3. Use R to set ghost component-luminance values. The
luminance of the light ghost on one side of VacMan and
the dark ghost on the other side are matched increments
and decrements: Lback 6 (R/100)*Lrange. For example, in
Figure 2C, R¼ 75%. Thus, for C¼ R/100¼ 0.75: 45 6 C
*45 ¼ 78.8 and 11.3 cd/m2, respectively. Similarly, the
light ghost (right) and dark ghost (left) are Lback 6 (1-
C)*Lrange¼ 45 6 0.25*45 ¼ 56.3 or 33.8 cd/m2.
Initially R was set to 80% and then adjusted (by 610%) on
each trial, using a one-up-one-down staircase procedure,
according to whether a response was consistent with reliance
on the FE or the AE. For R ¼ 75% (Fig. 2C) the AE sees a
substantially stronger white ghost; someone with balanced
vision would report that they perceive the whiter ghost on the
‘‘left’’ leading to a reduction in R on the next trial. Thus, R
converges on the level necessary for the stimulus delivered to
either eye to drive the report with equal probability. For an
observer neglecting the AE, R > 50% indicating that a stronger
signal is required in the amblyopic eye for that ghost to be
reported as whiter.
Note that each child performed one trial per minute with
the procedure restarting each time the child switched movies,
so the number of trials contributing to any one suppression
estimate varied according to the time spent watching a given
movie in one session. If the child chose a location in which no
ghost was presented, he or she was either not paying attention
or not viewing through the goggles (because balanced ghosts
were invisible without the 3D shutter glasses). The number of
such errors was used to quantify attention/compliance. The
system e-mailed the experimenter a daily update of the time
children had spent engaged in movie viewing and their
performance on this task.
We treated the first cohort of participants (group 1: n ¼ 8,
all anisometropes) for a maximum of 8 weeks. At standard
orthoptic assessments that occurred alongside BBV (see next
section), we observed gains in acuity and stereoacuity that did
not reach a plateau. Therefore, for the second group of
children (group 2: all combined or strabismic amblyopia) we
extended the maximum period of treatment to 24 weeks.
Orthoptic Assessment
An experienced orthoptist performed a battery of tests at
baseline (pretreatment) and after 4 and 8 weeks of therapy.
They assessed best-corrected visual acuity using a crowded
logMAR test at 3 m (Thompson v2000 software; Thompson
Software solutions, Hertfordshire, UK), stereoacuity using the
FIGURE 1. (A) Treatment system: a personal computer, 3D-capable monitor, response-keypad, infrared emitter, and goggle-mounted shutter-glasses.
(B) (Top) The child’s view through AEs and FEs. The system applied sufficient blur to the FE to match acuity with the AE. (Bottom) Although movies
are 2D, a shift in the relative position of each eye’s image modulates the perceived depth of the movie. The zero-disparity textured background is
also visible, which provides a vergence lock. Movie image  copyright 2008, Blender Foundation, www.bigbuckbunny.org, available under the
Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/).
FIGURE 2. The psychophysical tasks used (A, B) to establish blur level for the FE and (C) to quantify suppression during treatment. (A) Crowded
‘‘VacMan’’ stimulus used to measure acuity in the AE. (B) Stimuli used to estimate the blur level required to match the performance of the FE to the
AE. (C) Suppression/compliance task. VacMan is flanked by two ghosts either positioned on the left and the right (as shown) or above and below
(dashed outlines). Each ghost was a mixture of one dark and one light ghost presented to different eyes on each side (illustrated within the white
circles). We quantify suppression as the mixture of luminance (L)-increments and -decrements required for the child to be equally likely to report
either ghost as ‘‘whiter.’’ (D) Sample staircases for two observers. Gray text and horizontal line indicate the estimated balance point.
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Frisby near stereotest,49 and ocular motility and ocular
alignment at 3 m (distance) and 33 cm (near) using the prism
cover test. Finally, we attempted to make a clinical measure of
suppression using a Bagolini filter bar (also known as Sbisa bar)
(Haag-Streit UK, Harlow, UK). This test uses red filters of
increasing density to quantify the reduction in luminance of a
target (presented to the fixating eye) required to induce
diplopia. This test was difficult to administer (only seven of the
children approached were able to perform it). Given the small
sample size, and reports of poor test-retest reliability of this
test,50 we do not consider these data further.
Participants eligible for a longer course of treatment (group
2; see Results) were also assessed at 16 and 24 weeks. Treatment
was discontinued after 4 weeks if the acuity fell below baseline,
or if the interocular acuity difference (IOAD) had improved to
normal levels (0.2 logMAR or less). At subsequent visits, children
were considered to have reached a plateau if acuity failed to
improve by 0.1 logMAR from their preceding visit. Children who
were advised to discontinue home therapy were referred back
to the hospital eye clinic to receive standard occlusion therapy,
if IOAD was still 0.2 logMAR or greater or AE acuity did not
recover to within 0.1 logMAR.
Outcome Measures
We used crowded logMAR acuity as our primary outcome
measure. We expressed changes in visual function as follows:
 AE logMAR acuity.
 Residual IOAD after treatment.
 Proportion of deficit corrected, defined as (AEbaseline 
AEexit)/(AEbaseline  FEexit).51
In addition, we explored stereopsis (Frisby test) and
suppression (ghost task, described above). We also quantified
compliance as the mean time spent watching movies per day
(‘‘daily dose’’) and the mean cumulative time spent watching
movies (‘‘total dose’’) and adherence as the percentage of the
days that treatment was received. Other factors that may have
contributed to the outcome measures (treatment duration,
type of amblyopia, initial severity of amblyopia, and age) also
were evaluated51 and are described in the Supplementary
Materials.
RESULTS
Two children did not attend the 4-week appointment and were
excluded from analyses, leaving 22 children. Group 1 thus
consisted of seven children with anisometropic amblyopia
(mean age 9.5 years; 4 females). A total of 15 children were
included in group 2 (mean age 5.2 years), 6 with strabismic
amblyopia (mean age 5.75 years; 2 females) and 9 with
combined mechanism amblyopia (mean age 4.7 years; 6
females). Where necessary, results are reported separately for
children included in group 1 (allowed maximum 8 weeks) or 2
(allowed up to 24 weeks on treatment).
Acuity
Figures 3A and 3B plot the difference in logMAR acuity from
baseline (BL), as measured for each child during his or her
clinical assessments. Specifically, data for children with pure
anisometropic amblyopia (n¼ 7; square symbols) or strabismic
amblyopia (n¼ 6; triangle symbols) are reported in Figure 3A,
whereas those with combined mechanism amblyopia are in
Figure 3B (n ¼ 9; circle symbols). Individual declines or
improvements in vision are represented by values falling above
or below the dashed horizontal line, respectively (no change
from BL ¼ 0 logMAR acuity difference). The individual values
measured before starting and after completing BBV treatment
(entry versus exit logMAR acuity) are plotted in Figure 3C. As
per the study protocol, children were treated for up to either 8
weeks (group 1; n¼ 7: IDs 1–8 in Table 1) or 24 weeks (group
2; n ¼ 15: IDs 9–24). Among children in group 2, 5 did not
improve further after 8 weeks (IDs: 9, 10, 17, 19, and 24;
making 12 children in total released at this time point),
whereas 4 children remained in treatment for 16 weeks (IDs:
11, 16, 18, and 23) and 6 for 24 weeks (IDs: 12–15, 20, 22),
depending on the measured improvement in acuity. Note that
acuity continued to improve beyond 8 weeks for some
children, suggesting that those whose treatment was terminat-
ed at this point (because this was the limit of our approved
protocol for group 1) would have received further benefit from
continued treatment.
When data from all the children were combined (regardless
of amblyopia type, n ¼ 22), mean acuity in the AE improved
FIGURE 3. (A, B) Acuity difference in the AE compared with baseline (BL) during treatment; changes below or above the dashed line, respectively,
represent improvements or deteriorations in vision. Participants’ amblyopia type was pure anisometropic (n¼7; [A]: squares), pure strabismic (n¼
6; [A]: triangles), or combined (n¼ 9; [B]: circles). Thick lines show the mean change in acuity difference for each type of amblyopia (aniso. and
strab. in [A]; combined amb. in [B]). Symbol-color codes the age of participants (age indicated in parentheses, in legends of parts [A, B]; from blue-
younger to red-older children). Identity codes (1–24) are given next to individual lines and in the legends of (A) and (B) and label individual data
point in (C). Note that group 1 (A) is anisometropic (i.e., treated for a maximum of 8 weeks), and group 2 (A, B) is strabismic and combined (treated
for a maximum of 24 weeks; line length gives length of treatment). (C) Comparison of pre- and posttreatment acuity for each child. Points below the
diagonal line are improvement, with the shaded region indicating gains less than 0.15 logMAR (considered critical of test-retest reliability).44 The
dashed vertical line (at 0.6 logMAR) represents the cutoff between mild-to-moderate and severe amblyopia.
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from 0.78 6 0.35 to 0.51 6 0.34 logMAR, a significant mean
gain of 0.27 6 0.22 logMAR (1-sample paired t-test, t5.83, P <
0.001). Vision in the FE remained stable, improving slightly: the
mean gain (0.05 6 0.11 logMAR, mean baseline: 0.02 6 0.13
logMAR) was statistically (P ¼ 0.04) but not clinically (gain
<0.2 logMAR) significant. Mean acuity gain in severe ambly-
opia (bold in Table 1 for the n¼ 14 with acuity worse than 0.6
logMAR) was 0.32 60.24 logMAR, versus 0.18 60.14 logMAR
in mild-to-moderate amblyopia (n¼8). Acuity gains for group 1
(whose treatment was curtailed at 8 weeks, all anisometropic
amblyopes) was 0.26 6 0.28, and for group 2 (maximum
treatment of 24 weeks, combined and strabismic amblyopes)
was 0.27 6 0.19 logMAR. There was no significant difference
in acuity gains between group 1 and 2 (2-sample t-test(df:20), P¼
0.863).
After treatment, 15 children reached IOAD  0.6 logMAR (6
of whom started with severe amblyopia), including 7 children
(1 severe) who recovered to 0.3 logMAR. No further
treatment was required for ID15, whose IOAD improved from
0.34 to 0.1 logMAR and ID1, whose AE acuity reached 0.04
logMAR (although final IOAD was 0.24 logMAR). The mean
‘‘proportion of deficit corrected’’ was 32% 6 26%, with
substantial gains (>60%) in two children (IDs 15 and 22, 71%
and 69%), and poor (<10%) in three children (IDs 8, 19 and
24). In 7 children, improvement was between 10% and 30%,
and in the remaining 10 children, between 30% and 60%.
Maintenance of Acuity Gains After End of
Treatment
At the time of writing, clinical follow-up data were available for
11 children, 7 of whom received standard treatment following
BBV. Their mean acuity gain was 0.39 6 0.25 logMAR at
completion of BBV treatment and 0.34 6 0.30 logMAR after an
additional mean follow-up time of 47 6 10 weeks logMAR.
Seven children attended a follow-up at 2 years (mean 95 6 30
weeks after stopping BBV), with þ0.01 6 0.23 logMAR mean
change in acuity logMAR from BBV completion (four of seven
gained 0.15 6 0.1 logMAR; three of seven regressed 0.23 6
0.16 logMAR).
Stereoacuity
Only children with purely anisometropic amblyopia (group 1)
had measurable stereoacuity at baseline, with a median of 170
arcsec (interquartile 230 arcsec; Fig. 4). Following treatment,
six of seven children had significantly improved stereoacuity.
Overall (n ¼ 7), the median stereoacuity value at exit was 85
arcsec (interquartile 30 arcsec) and mean improvement was
165 6 182 arcsec, significant with a Wilcoxon signed rank test
(paired, z¼ 2.298, P¼ 0.0215 at a¼ 0.05). The one participant
whose stereoacuity did not improve (ID3) had good stereo-
acuity at entry. We transformed data to logarithmic seconds of
arc to calculate ‘‘real change’’ in stereoacuity and to allow for
comparisons between consecutive visits. Prior studies have
found the test-retest reliability of stereoacuity measurements
using the near Frisby test in children to be 0.3 log arcsec, with
‘‘real change’’ defined as a doubling of stereoacuity expressed
in octaves.52 Here, mean stereoacuity gain was 0.40 log arcsec
(60.32), with all but ID3 exhibiting an improvement in
stereoacuity ‡1 octave (Fig. 4B). Mean improvement was 1.33
octaves (i.e., a factor of 2.6 improvement). Of the children
having unmeasurable baseline stereopsis, three showed
progression after BBV treatment, reaching 600 (ID9), 85
(ID11), and 110 (ID14) arcsec at 1-year follow-up. For the
remaining children, the Frisby measure was inconclusive. The
gain in stereoacuity significantly correlated with both the initial
level of acuity in the AE (r¼ 0.97, P¼ 0.0003) and its absolute
improvement (r ¼ 0.85, P ¼ 0.02), but did not correlate with
the proportional gain in acuity (r¼ 0.44, P ¼ 0.32).
Interocular Suppression
Figure 5 shows individual suppression data from the ghost task.
Note that ID4 initially did not comply with this task and their
(incomplete) data were excluded from the analyses of
suppression. The mean suppression at entry was 72.3% (SD
12.02%) and at exit was 72.6% (SD 12.3%). Overall, these
values are in line with comparable estimates for adult
amblyopes (e.g., 75%)25 and not significantly different from
one another (t-test(df:20): P ¼ 0.98). We do not observe the
substantial reductions in suppression observed in other studies
of binocular therapy.53 Indeed, a statistically significant
FIGURE 4. Stereoacuity (when measurable) for children who completed treatment. (A) Before, during, and after treatment (at 0, 8, and 16 weeks
respectively), (B) Pre- versus posttreatment. All children for whom data are shown (n¼ 7) had purely anisometropic amblyopia (group 1). Symbols
are colored to reflect the relative age of each child compared with their peers (red ¼ oldest). Boxed legend in (A) shows individual gain in
stereoacuity (arcsec). For six participants, stereoacuity gains exceeded the test-retest variability threshold of 0.3 log arcsec and a step of one octave
(shaded area).
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reduction in interocular suppression was observed in only 6 of
the 22 children, of whom 4 had combined mechanism and 2
purely strabismic amblyopia. Further, 5 children showed a
significant increase in suppression (ID4 excluded), while 10
children showed no significant change. For each individual, we
calculated the linear regression trend line (bold lines in Fig. 5)
for daily estimates of R (quantifying the patient’s binocularity:
0% fully reliant on AE, 100% fully reliant on the FE).
We performed additional analyses to examine changes
within and across sessions. First, for within-session changes,
we analyzed runs containing at least 30 trials (‘‘long sessions’’;
an average of 36.5% of all runs across 21 children) and divided
these runs into three parts. We then compared the average
stimulus balance in the second and third part (excluding the
first part where the staircase may not be close to convergence),
computing a linear regression between values to determine if
the slope was significantly different from 0. According to this
analysis, for each child (excluding ID4) an average of 9% of
‘‘long sessions’’ involved a significant change in suppression
within session. However, such changes were not biased toward
increasing suppression (49.8% 6 27.8% of cases) or decreasing
suppression (50.3% 6 27.8%). Second, across sessions, we
note that Kehrein et al.54 reported an increase in suppression
during the first 30 days of occlusion therapy, followed by a
return to baseline in the following month. We performed a
similar analysis comparing suppression over the first and
second 30 days of treatment using regression analysis. Mean
slopes over the first and second 30 days were 0.0688 (SD
0.4220) and 0.0018 (SD 0.6245), respectively, a nonsignificant
difference (t(20)¼0.41, P ¼ 0.68). Thus, occlusion may exert
greater (but short-lived) influence on interocular suppression
than binocular therapies.
Figure 6A shows suppression at entry versus exit from
treatment (ID4 did not have a complete set of data and was
excluded). There was no systematic trend in the change of
suppression with treatment: suppression decreased in some
children (points below the unity line) but increased in others
(points above unity). Figure 6B plots improvement in acuity for
the AE versus the difference in suppression, obtained by
averaging each child’s daily suppression measures. There was a
nonsignificant tendency for more improvement in acuity to be
associated with modified suppression (Pearson’s r¼ 0.19, P ¼
0.40; ID4 excluded), especially when suppression significantly
changed, either increasing (r¼0.47; P¼ 0.80) or decreasing
(r¼0.13; P¼ 0.35). For observers with stable suppression (n
¼ 10), we observed a mean gain in acuity of 0.16 6 0.15
logMAR, whereas for observers whose suppression decreased
(n¼ 6) the change in acuity was 0.40 6 0.15 logMAR and for
those whose suppression increased (n¼ 5; ID4 excluded) the
change was 0.22 6 0.18 logMAR. A post hoc power calculation
for Pearson’s r supports our analyses being appropriate to
detect higher correlations (for n ¼ 22  1(df), r ¼ 0.58
significant, with 80% power). In Figure 6B, we highlight the
range of uncertainty for each child by adding error bars
(denoting 95% confidence intervals; horizontal bars for acuity
gain, verticals for change in suppression). To do this, we first
estimated confidence on acuity gain from the typical test-retest
variability of logMAR acuity results in children (60.15
FIGURE 5. Day-by-day estimates of suppression (R: % reliance on FE, see Treatment Regimen) for participants with anisometropia (upper row;
group 1) and/or with strabismus (group 2). Participants’ ID numbers are indicated at the bottom left of each subplot. Here, 50% means ‘‘balanced
vision,’’ 100% indicates complete reliance on the FE (i.e., complete suppression of the AE), and 0% indicates complete suppression of the FE. Green
symbols pool data within three periods (beginning, middle, end; binned around the individual duration of BBV; note ID4 was not compliant for a
period, hence the middle bin is missing). We derived black trend lines from linear regression analysis of daily estimates. An asterisk after the child’s
ID indicates a significant reduction in suppression for that child (P < 0.05).
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logMAR), and on change in suppression by resampling our
indices. We then bootstrapped on pairs of derived values,
obtaining at each repetition two sets of changes to find the
relative correlation (one set from acuity-paired values and one
from suppression-paired values). The mean r across repetitions
was 0.161 (mean SD 0.132) confirming the lack of a strong
correlation.
Compliance
On average, adherence (calculated as the percentage of days
when treatment was received) was 68.0% 6 12.2%, meaning
that children watched a movie on more than two-thirds of the
days on which the equipment was available to them. The mean
total dose (across the whole treatment duration) was 75 hours
14 minutes, with a mean daily dose of 54 6 14.5 minutes
(range, 25–89 minutes). Figure 7A shows that none of the
children used the system for less than 20 minutes per day (30%
of the prescribed dose). Good compliance (20–50 minutes)
was demonstrated by 7 children, and excellent compliance
(>50 minutes a day) by 15 children, with mean adherence of
63.4% and 70.5%, respectively. Five children exceeded the
prescribed dose. A previous study on a monocular video-game
therapy for amblyopia showed a marginally significant corre-
lation between gain in acuity and longer daily sessions in
children.42 We find that a greater final gain in acuity was not
significantly associated with greater daily dose (r¼ 0.234, P ¼
0.296; Fig. 7A) or with a higher percentage of days on
treatment (r ¼ 0.0001, P ¼ 0.9998). One might expect
dedication to therapy to improve with age, but we did not
find significant correlations of age either with the daily dose (r
¼0.05, P ¼ 0.8) or with the number of treatment days (r ¼
0.38, P ¼ 0.08).
As a measure of attention paid to the task, we classified
responses on the ghost task either as ‘‘valid’’ (the child
indicated a ghost in a location where there was one) or as
‘‘lapses’’ (the child indicated a position were no ghost was
present). On average, 23.1% of responses over all runs were
‘‘lapses’’ (SD 20.7%). Figure 7B shows a significant negative
correlation between the proportion of ‘‘lapses’’ and the age of
the child (r ¼ 0.54, P ¼ 0.01). Although we note a high
number of lapses, particularly in some younger children, this
FIGURE 6. Estimates of suppression for 21 children (ID4 excluded; IDs numbers to label the correspondent data points; markers colored from blue-
younger to red-older children across all recruited children) (A) Suppression (R) is similar at entry compared with exit from treatment. (B) There is
only a modest correlation of gain in visual acuity (VA) with change in suppression (r ¼ 0.193), which does not reach statistical significance (P ¼
0.402). The horizontal dashed line represents the level of ‘‘balanced vision.’’ VA gains outside of the shaded region are considered clinically
significant (‡ 0.2 logMAR). Error bars indicate 95% confidence intervals on acuity (horizontal) and suppression (vertical) estimates.
FIGURE 7. Compliance and attention. (A) Daily dose in minutes is plotted against acuity (VA) gains in logMAR for the AE. The trend line shows how
a higher daily dose (individual mean number of minutes per day spent watching movies) was associated with greater improvement in VA. (B)
Percentage of lapse trials on the whitest-ghost task (‘‘invalid responses,’’ i.e., where the child either indicated a location where a ghost was not
present or did not respond at all) as a function of age. Younger children are more prone to lapsing, possibly indicating poorer attention to the task.
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does not seem to have greatly affected our estimates of
suppression (which remain stable across many days; Fig. 5). In
particular, although some children with noisier suppression
data did make more lapses (e.g., IDs 15, 22), others did not
(e.g., IDs 10, 11). This is because our suppression estimate was
tolerant of lapses because lapsing generated ‘‘no-response’’
(not a random response) so that the same stimulus level was
presented until a valid response was made, and run lengths
were long enough (average 30 trials, SD 14.8 trials) that
staircases converged even with frequent lapsing. We note that
children generally tolerated the interruption of the ‘‘ghost’’
task surprisingly well, possibly because they are accustomed to
media content being regularly interrupted by commercials.
DISCUSSION
We describe a novel treatment for amblyopia, BBV therapy,
which matches stimulation across the eyes and consists of 1
hour per day viewing ‘‘binocularly balanced’’ movies at home
through shutter glasses. The procedure involves the blurring of
the image received by the FE, at a level such that monocular FE
acuity for the blurred stimulus was equal to monocular acuity
for the AE (for an unfiltered stimulus as measured at treatment
induction). Twenty-two children (3–11 years), with anisome-
tropic, strabismic, or combined amblyopia, completed our
study, spending on average 75 hours 14 minutes on treatment,
which led to a mean gain in acuity in the AE of 0.27 6 0.22
logMAR. This gain is clinically significant (i.e., >0.2 logMAR),55
and matches or exceeds those reported using alternative
binocular treatments (Table 2). In terms of rate of improve-
ment, although patching requires 120 hours of treatment for
every one line of logMAR acuity gained,56 our approach is
more than four times faster, yielding a similar benefit in only 28
hours of movie viewing.
In terms of stereoacuity, we obtained reliable measures
(pre- and posttreatment) only in children with pure anisome-
tropic amblyopia, who frequently maintain a degree of
binocularity, especially at low spatial frequencies,57 which
remain visible to both eyes. For these children, stereoacuity
reached normal values49 in all but one child, exceeding reports
for occlusion13 and other binocular therapies (see Table 2).
The treatment duration varied across children, depending
on the responsiveness of each child, as evaluated during
orthoptic assessment in clinic, and between groups of
amblyopia type, to address concerns about inducing diplopia.
A pilot group of children (group 1) was treated for 8 weeks
only (according to the standard interval adopted in clinic to
evaluate a visual treatment). Although acuity improved in six of
seven of these children (mean gain: 0.3 6 0.26 logMAR; ID8
stable), we do not report a significant change in suppression.
In the absence of any adverse events, we went on to apply BBV
to children in group 2, with strabismic (n ¼ 6) and combined
mechanism amblyopia (n ¼ 9), looking at longer-term effects
after up to 24 weeks on treatment.
This difference in treatment duration limits the validity of
comparing responsivity across children, especially because
gains had not plateaued in at least some children who were
released from BBV. However, we can still consider the effect of
treatment length and compliance on the therapeutic outcome.
Standard occlusion therapies, which are likely to improve
acuity in 50% to 85% of children,58 are fundamentally limited
by levels of concordance (i.e., agreement on treatment
regimen between patient and clinician) falling below 50%,56
and compliance, especially at a young age (<50% in 4- to 7-
year-old children16). Recent studies of various binocular
treatments have shown that children whose compliance is
less than 50% either showed significantly lower gain in logMART
A
B
L
E
2
.
C
u
rr
e
n
t
an
d
P
ro
p
o
se
d
T
re
at
m
e
n
ts
fo
r
A
m
b
ly
o
p
ia
O
cc
lu
si
o
n
,
P
a
tc
h
in
g
o
r
A
tr
o
p
in
e
G
a
m
e
P
la
y
a
n
d
P
e
rc
e
p
tu
a
l
L
e
a
rn
in
g
A
S
T
iB
IT
B
B
V
M
e
th
o
d
o
lo
g
y
E
n
h
an
c
e
d
u
sa
ge
o
f
A
E
R
e
p
e
ti
ti
v
e
g
am
e
p
la
y
an
d
p
sy
ch
o
p
h
ys
ic
al
ex
p
e
ri
m
e
n
ts
e
it
h
e
r
w
it
h
o
c
c
lu
si
o
n
o
f
F
E
*
o
r
n
o
t*
*
V
id
e
o
g
am
e
s
w
it
h
e
le
m
e
n
ts
d
is
tr
ib
u
te
d
ac
ro
ss
e
ye
s;
c
o
n
tr
as
t
im
b
al
an
c
e
is
p
ro
g
re
ss
iv
e
ly
re
d
u
c
e
d
M
o
d
if
ie
d
v
id
e
o
an
d
in
te
ra
c
ti
v
e
g
am
e
s
(o
n
ly
A
E
se
e
s
k
e
y
d
e
ta
il
s
o
f
th
e
sc
e
n
e
)
M
o
v
ie
v
ie
w
in
g
in
b
al
an
c
e
d
st
e
re
o
sc
o
p
ic
p
re
se
n
ta
ti
o
n
(F
E
v
is
io
n
b
lu
rr
e
d
)
M
ai
n
p
u
b
li
sh
e
d
st
u
d
ie
s
[9
–
1
1
]
*
[1
8
,
2
0
,
fo
r
P
L
re
v
ie
w
:
4
0
,
4
2
]
**
[4
3
]
[3
3
,
3
4
,
3
6
,
3
7
]
[3
9
]
P
re
se
n
t
st
u
d
y
M
e
an
V
A
g
ai
n
in
lo
g
M
A
R
u
n
it
s
(i
n
d
if
fe
re
n
t
st
u
d
ie
s)
~
0
.2
–
0
.3
~
0
.2
0
.1
4
(0
.0
8
–
0
.1
9
)
0
.0
8
(v
id
e
o
:
0
.1
-g
am
e
s:
0
.0
6
)
0
.2
7
C
o
m
p
li
an
c
e
(d
o
se
re
c
e
iv
e
d
v
s.
p
re
sc
ri
b
e
d
)
4
4
%
[1
6
]
(~
5
0
%
–
1
0
0
%
)
(1
0
0
%
)
>
9
0
%
(e
x
ac
tl
y
n
.s
.;
su
p
e
rv
is
e
d
)
9
0
%
(r
e
m
o
te
ly
su
p
e
rv
is
e
d
)
R
e
c
u
rr
e
n
c
e
fo
ll
o
w
in
g
lo
ss
o
f
V
A
g
ai
n
~
3
0
%
at
1
ye
ar
[1
4
,
1
5
]
Sm
al
l
d
e
c
re
m
e
n
ts
to
n
il
n
.s
.
A
t
1
0
w
k
:
V
id
e
o
-0
.0
3
/g
am
e
s-
n
il
A
t
4
7
w
k
(n
¼
7
):
0
.0
5
A
ge
,
‘‘
b
e
st
-f
it
’’
P
re
sc
h
o
o
l
ch
il
d
re
n
A
d
u
lt
s
A
d
o
le
sc
e
n
t/
ad
u
lt
s
P
re
sc
h
o
o
l/
sc
h
o
o
l
ch
il
d
re
n
P
re
sc
h
o
o
l/
sc
h
o
o
l
ch
il
d
re
n
T
re
at
m
e
n
t
d
u
ra
ti
o
n
~
1
2
–
2
4
w
k
(2
–
1
2
h
/d
)
U
p
to
3
9
w
k
(P
L
:
6
–
5
0
h
,
u
p
to
5
2
2
h
)
1
–
9
w
k
(0
.5
–
2
h
/s
e
ss
io
n
)
6
w
k
(3
0
m
in
/w
k
)
8
–
2
4
w
k
(1
h
/d
)
Se
tt
in
g
(s
u
p
e
rv
is
io
n
re
q
u
ir
e
d
?)
C
li
n
ic
al
(y
e
s)
C
li
n
ic
al
(a
n
d
h
o
m
e
[4
2
,
4
3
])
(y
e
s)
C
li
n
ic
al
(h
o
m
e
[3
7
])
(r
e
c
o
m
m
e
n
d
e
d
)
C
li
n
ic
al
(y
e
s)
H
o
m
e
(r
e
c
o
m
m
e
n
d
e
d
)
D
at
a
ar
e
p
o
o
le
d
fr
o
m
re
p
re
se
n
ta
ti
ve
st
u
d
ie
s
ci
te
d
in
th
e
ar
ti
cl
e;
th
e
ta
b
le
is
n
o
t
a
co
m
p
le
te
re
vi
ew
o
f
th
e
cu
rr
en
t
lit
er
at
u
re
.C
o
lu
m
n
1
d
es
cr
ib
es
o
cc
lu
si
o
n
th
er
ap
y
(i
.e
.,
cu
rr
en
t
cl
in
ic
al
p
ra
ct
ic
e)
,c
o
lu
m
n
2
sh
o
w
s
ap
p
ro
ac
h
es
th
at
su
p
p
le
m
en
t
o
cc
lu
si
o
n
,
an
d
co
lu
m
n
s
4
–6
lis
t
al
te
rn
at
iv
es
to
o
cc
lu
si
o
n
(i
.e
.,
b
in
o
cu
la
r
tr
ea
tm
en
ts
).
R
ef
er
en
ce
n
u
m
b
er
s
ar
e
in
b
ra
ck
et
s.
n
.s
.,
n
o
t
sp
ec
ifi
ed
;
V
A
,
vi
su
al
ac
u
it
y;
A
E
,
am
b
ly
o
p
ic
ey
e;
F
E
,
fe
llo
w
ey
e.
Binocular Therapy for Childhood Amblyopia IOVS j June 2017 j Vol. 58 j No. 7 j 3039
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936282/ on 06/16/2017
acuity38 or required longer treatment durations to reach
comparable outcomes.59 In older children, the success of
monocular training (in addition to patching) was related to the
total amount of training (across sessions), provided a minimum
daily compliance level of 15 minutes of practice per session
was met.42 In our study, on average, children who spent 8 or
16 weeks on BBV showed high levels of compliance (87% 6
21% and 84% 6 28%), with similar gains in AE acuity (0.2 6
0.24 and 0.24 6 0.11 logMAR, respectively). Those eligible for
24 weeks received 98% 6 46% of the prescribed dose and
gained 0.41 6 0.16 logMAR (see also Supplementary Materi-
als). Interestingly, those children whose BBV treatment lasted
longer spent a higher proportion of days on treatment (66%,
70%, and 71%, respectively over 8, 16, and 24 weeks). These
results suggest that high levels of compliance, as both daily and
total perseverance, can produce positive treatment outcomes
(although such correlations did not reach significance in our
study, perhaps due to the generally high levels of compliance).
More generally, alternative treatments (to replace or augment
occlusion) engage higher levels of compliance than occlusion
alone.60 Leaving open the question of whether occlusion is
necessary, these studies highlight the importance of compli-
ance in amblyopia treatment. Given the lack of clarity
regarding the mechanism supporting improvements in vision,
further study is required to determine the extent to which
compliance contributes to the superior (more rapid) thera-
peutic response from binocular therapies.
Although it is widely assumed that the likelihood of positive
treatment outcomes decreases with age,61 recent interventions
have highlighted the possibility of improving vision in
amblyopia at almost any age.62 As highlighted in the
introduction, ‘‘perceptual learning’’ (PL) approaches (involving
monocular training on gameplay41,42 or psychophysical
tasks18,40) have proven effective in this regard. Gains obtained
on the trained task generally transfer to acuity (showing
approximately 1–2 logMAR lines of improvement, after
approximately 30–50 hours training depending on the severity
of amblyopia).40 Dichoptic PL also has been found to improve
stereoacuity.43 Similar improvements have been found with
binocular interventions, such as ‘‘antisuppression’’ (AST)63 or
interactive-binocular (I-Bit)39 therapies that seek to reduce a
notional suppressive drive from the FE by equating the
visibility of stimuli across the eyes. However, related studies,
including games therapy in children37 and adults59,64 did not
exclude participants who had previously undergone occlusion
therapy, making it impossible to disentangle the influence of
previous treatments on outcome. Further, only a few previous
studies checked for stable vision before treatment induc-
tion.37,38 This leaves open the possibility that at least some of
the therapeutic benefits of the treatment originate from
ongoing benefits of optical treatment. Note that we included
only children with no history of occlusion therapy and whose
acuity stabilized after minimum 16 weeks of optical treatment.
In terms of stereoacuity, only children with measurable
(generally poor) stereoacuity at entry showed significant
improvements following our BBV treatment. This is consistent
with earlier work (with occlusion51 or alternative treatment44),
which indicated that the initial level of vision may limit
treatment outcomes. Among PL approaches, there is evidence
for a small advantage of dichoptic game play over monocular
movie viewing in improving stereoacuity,43 although monoc-
ular game play can also be effective.40 AST treatment has been
shown to significantly improve stereoacuity in adults33–35 but
not always in children.37,38 Further research (e.g., within
randomized controlled trials) is needed to determine which
components of these therapies are critical for triggering
improvements in specific visual functions (such as stereoacui-
ty) and to establish the wider applicability of these treat-
ments.65
To equalize acuity across the two eyes, we individualized
the level of Gaussian blur applied to the image viewed by the
FE during movie viewing (i.e., the high spatial fequencies were
attenuated in proportion to the AE acuity deficit). This is in
contrast to the fixed blur levels used in treatments that rely on,
for example, Bargerter translucent filters.66 In contrast, ASTs
manipulate the contrast of the signal to balance visibility across
the eyes, and update this level as the child’s vision changes
during therapy. The fact that we observe substantial gains in
acuity indicates that fixed levels of blur penalization and
contrast penalization are both effective for treatment.
Whether and how these methods are related to suppression
in amblyopia is hotly debated. Some hold that suppression is a
cause of amblyopia31,67 and that ASTs strengthen binocular
combination by breaking this suppression, allowing monocular
and binocular vision to improve. If this were the case, we
would expect better outcomes (i.e., improved acuity) to be
associated with greater reductions in suppression. We, like an
earlier study,53 do not find strong evidence for such an
association, although we note that our approach did not
produce substantial changes in suppression at all, unlike at
least some binocular gaming therapies53 and occlusion
therapies.54 That our therapy is effective in the absence of
changes in suppression is, however, consistent with the idea
that suppression cannot be the sole cause of amblyopic visual
loss. An alternative view is that suppression is a consequence
of amblyopia to avoid diplopia.32 If so, a temporary disruption
of binocularity (e.g., using repetitive transcranial magnetic
stimulation) should have no impact on monocular function.
That it does68 supports the presence of reduced (not lost)
functionality of the AE, possibly as a result of suppression.
As mentioned above, there is no consensus as to the best
way to quantify interocular suppression. The method we use to
quantify suppression is related to one we have developed
previously25 and uses dichoptic ‘‘dark and light’’ symbol-pairs
(‘‘ghosts’’). We quantify suppression as the contrast ratio that
leads the viewer to be equally likely to report that the symbol
presented to either eye is ‘‘the whitest.’’ Although we cannot
rule out that the task used to probe suppression will influence
the pattern of suppression reported,69 we think it is unlikely
that performance on these different dichoptic tasks is mediated
by fundamentally different mechanisms. A further study
comparing the currently available methods to measure
suppression (clinical and psychophysical) is ongoing. In the
present study, we found that the gain in vision achieved under
BBV did relate to reduced suppression; however, the correla-
tion was low and failed to reach significance. The absence of a
significant relationship between suppression and acuity
outcomes greatly limits the risk of inducing intractable diplopia
as an adverse side effect from a binocular therapy.
If gains in acuity do not originate from a reduction in
suppression, what does produce them? Current theories of the
neural basis of amblyopia focus on the consequence of
abnormal input from the AE for neural encoding within the
lateral geniculate nucleus and primary visual cortex (V1). The
following are candidate models: a reduction in the number
and/or sensitivity of neurons driven by the AE (undersam-
pling),70–72 positional disorganization of visual receptive fields
and associated distortions of retinotopic mapping (disar-
ray),73–75 and increased variability in the response of binocular
cortical neurons (elevated noise).76 Animal models of ambly-
opia have produced results to support each of these
mechanisms,30 although the magnitude of these deficits in
V1 rarely matches the scale of the behavioral deficits,
suggesting an additional role for brain areas beyond V1.27 In
human vision, Clavagnier et al.73 recently reported findings
Binocular Therapy for Childhood Amblyopia IOVS j June 2017 j Vol. 58 j No. 7 j 3040
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936282/ on 06/16/2017
from functional magnetic resonance imaging population
receptive field (pRF) mapping (in vivo estimation of visual
receptive field size and density)77,78 from the FE and AE of
patients with amblyopia. They observed larger pRFs in the
fovea of amblyopia patients across areas V1 to V3, but normal
cortical magnification across these areas, which could arise
either through undersampling, positional disarray, or both.
This fits with the more general finding of increased receptive
field sizes in binocular V1 neurons following retinal lesions.79
Given the dependency of the size of RFs (and by extension
pRFs) on visual experience in these studies, we consider the
reduction in RF size to be the most reasonable current
candidate for the mechanism producing therapeutic response.
This in turn could be driven by reductions in undersampling
and/or disarray within a range of cortical regions, as above.
Importantly, the dissociation between suppression and acuity
gains in our study suggests that although suppression may play
a causal role in these amblyopic deficits,31 the mechanism
underlying such deficits can be altered by treatment without
concomitant changes in binocularity that modify suppression.
CONCLUSIONS
Our BBV treatment engages high levels of compliance and
leads to substantial gains in visual function after a relatively
short period of treatment. BBV is currently the only
unsupervised binocular vision treatment that also supports
remote monitoring of compliance and suppression. Our
findings thus far indicate that a reduction in interocular
suppression is not the basis of the observed improvements in
visual acuity.
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Binocular Therapy for Childhood Amblyopia Improves 
Vision without Breaking Interocular Suppression: 
Supplemental materials 
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Steven C. Dakin 
 
Visual Outcome: Other Factors  
Supplemental Figure 1 summarises how age, type and severity of initial amblyopia and 
treatment durations influenced outcome. Of the children who stopped after 8 weeks (N=12), 
7 from Group 1 were not allowed to continue based on our protocol, while 5 from Group 2 
were released due to a lack of further improvement. The mean gain in acuity after 8, 16 or 
24 weeks was 0.20±0.24, 0.24±0.11 or 0.41±0.16 LogMAR respectively (see Supp. Fig. 1A). 
Paired comparisons did not reveal a significant influence of the duration of the treatment on 
the final gains in acuity (not even between 24 versus 8 weeks, whose relative mean acuity 
gains showed the largest reciprocal difference; p=0.07). Differences in the maximum 
permissible period of treatment across groups precludes detailed comparison between 
groups. However, dependence of treatment response on the type of amblyopia is 
summarised in Supplemental Figure 1B. Visual acuity improved on average by 0.26 (SD 
0.28), 0.34 (SD 0.21) or 0.23 (SD 0.17) LogMAR respectively in children with anisometropic, 
strabismic or combined-mechanism amblyopia. A two-sample paired t-test indicated there 
was no statistical significance between the mean-gain achieved for each type of amblyopia 
(anisometropic vs strabismic, p=0.54; anisometropic vs combined, p=0.80; strabismic and 
combined, p=0.26). There was no significant dependence of the severity of initial amblyopia 
with either the final absolute improvement in vision (mean acuity gain in the AE; R2=0.13, p = 
0.09; see Supp. Fig. 1C) or the final proportion of deficit corrected (R2=0.0006, p = 0.91).  
 
Lower age has been associated with higher probability of a successful treatment, possibly 
preventing the applicability of a treatment in adults: compliance (e.g. to patching) reduces 
with increasing age (Wallace et al. 2013, Stewart et al., 2005, Scheiman et al., 2005) and so 
does cortical plasticity (Lewis et al., 2005). Using regression analysis (least-squares fitting) 
we found that the age of participants did not differentially influence the change in acuity in 
the AE (R2= 0.001, p(F=0.03)  =0.87; see Supp. Fig. 1D). Accordingly, there was no 
dependence of age for children in Group 1 (mean age 9.46±1.93 yrs) or Group 2 (mean age 
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936282/ on 06/16/2017
5.12±1.97 yrs), on the final gain in acuity in the AE (two-sample t-test: p=0.86). Within Group 
1, we did however find an effect of age on stereoacuity measurements (Wilcoxon-paired, 
p=0.02 at α=0.05), though this was not measureable in Group 2. Finally, we considered the 
possibility that suppression changed with age by taking the individual suppression index 
averaged over the daily measures, for the duration of BBV treatment. Here we found no 
significant dependence of age on suppression (R2= 0.14, p (F=3.21) =0.09). 
 
 
Supplemental Figure 1 Other factors that may have influenced treatment outcome (A,B: mean improvement or 
C, D: individual gain). A: Longer treatments led to greater but not significantly different gains in visual acuity. B: 
Relations between the type of amblyopia and the improvement in VA (none were significant). The dashed lines 
(in A and B) show the mean test-retest reliability for acuity tests in children. Error bars show one standard error of 
uncertainty. C: Severity of amblyopia (initial VA in the AE) showed moderate influence on acuity gain in the AE, 
though this was not significant (R2= 0.134, p=0.09). D: Age (yrs) was not significantly correlated (R2= 0.001, 
p=0.87) with acuity gain in the AE.  
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